Roth Capital Raises PT on Galena Biopharma (GALE) Following Mills Pharmaceuticals Purchase
Tweet Send to a Friend
Roth Capital maintains its Buy rating on Galena Biopharma (Nasdaq: GALE), but raises its price target from $7 up to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
